Terms: = Breast cancer AND SERPINE1, PAI, PAI-1, PAI1, PLANH1 AND Clinical Outcome
17 results:
1. Patient-derived scaffolds influence secretion profiles in cancer cells mirroring clinical features and breast cancer subtypes.
Persson E; Gregersson P; Gustafsson A; Fitzpatrick P; Rhost S; Ståhlberg A; Landberg G
Cell Commun Signal; 2021 Jun; 19(1):66. PubMed ID: 34090457
[TBL] [Abstract] [Full Text] [Related]
2. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/pai-1.
Ettl J; Klein E; Hapfelmeier A; Grosse Lackmann K; Paepke S; Petry C; Specht K; Wolff L; Höfler H; Kiechle M
PLoS One; 2017; 12(9):e0183917. PubMed ID: 28877230
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic impact of the inclusion of uPA/pai-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.
Viala M; Alexandre M; Thezenas S; Lamy PJ; Maran-Gonzalez A; Gutowski M; Colombo PE; Romieu G; Jacot W; Guiu S
Breast Cancer Res Treat; 2017 Oct; 165(3):611-621. PubMed ID: 28685212
[TBL] [Abstract] [Full Text] [Related]
4. Impact of guideline-based use of uPA/pai-1 on patient outcome in intermediate-risk early breast cancer.
Kolben T; Augustin D; Armbrust R; Kolben TM; Degenhardt T; Burgmann M; Goess C; Ditsch N; Kates R; Harbeck N; Wuerstlein R
Breast Cancer Res Treat; 2016 Jan; 155(1):109-15. PubMed ID: 26643086
[TBL] [Abstract] [Full Text] [Related]
5. Plasma plasminogen activator inhibitor-1 (pai-1) levels in breast cancer - relationship with clinical outcome.
Ferroni P; Roselli M; Portarena I; Formica V; Riondino S; LA Farina F; Costarelli L; Melino A; Massimiani G; Cavaliere F; Palmirotta R; Guadagni F
Anticancer Res; 2014 Mar; 34(3):1153-61. PubMed ID: 24596353
[TBL] [Abstract] [Full Text] [Related]
6. Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism.
Ibrahim SA; Yip GW; Stock C; Pan JW; Neubauer C; Poeter M; Pupjalis D; Koo CY; Kelsch R; Schüle R; Rescher U; Kiesel L; Götte M
Int J Cancer; 2012 Sep; 131(6):E884-96. PubMed ID: 22573479
[TBL] [Abstract] [Full Text] [Related]
7. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (pai-1) in human breast carcinomas and their clinical relevance.
Andres SA; Edwards AB; Wittliff JL
J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
[TBL] [Abstract] [Full Text] [Related]
8. Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis.
Castello-Cros R; Bonuccelli G; Molchansky A; Capozza F; Witkiewicz AK; Birbe RC; Howell A; Pestell RG; Whitaker-Menezes D; Sotgia F; Lisanti MP
Cell Cycle; 2011 Jun; 10(12):2021-34. PubMed ID: 21646868
[TBL] [Abstract] [Full Text] [Related]
9. uPA and pai-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.
Annecke K; Schmitt M; Euler U; Zerm M; Paepke D; Paepke S; von Minckwitz G; Thomssen C; Harbeck N
Adv Clin Chem; 2008; 45():31-45. PubMed ID: 18429492
[TBL] [Abstract] [Full Text] [Related]
10. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
[TBL] [Abstract] [Full Text] [Related]
11. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and pai-1.
Ryan BM; Konecny GE; Kahlert S; Wang HJ; Untch M; Meng G; Pegram MD; Podratz KC; Crown J; Slamon DJ; Duffy MJ
Ann Oncol; 2006 Apr; 17(4):597-604. PubMed ID: 16403812
[TBL] [Abstract] [Full Text] [Related]
12. New data on chemotherapy in the adjuvant setting.
Piccart MJ; Sotiriou C; Cardoso F
Breast; 2003 Dec; 12(6):373-8. PubMed ID: 14659108
[TBL] [Abstract] [Full Text] [Related]
13. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract] [Full Text] [Related]
14. clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.
Harbeck N; Krüger A; Sinz S; Kates RE; Thomssen C; Schmitt M; Jänicke F
Onkologie; 2001 Jun; 24(3):238-44. PubMed ID: 11455216
[TBL] [Abstract] [Full Text] [Related]
15. Functional evaluation of plasmin formation in primary breast cancer.
Chappuis PO; Dieterich B; Sciretta V; Lohse C; Bonnefoi H; Remadi S; Sappino AP
J Clin Oncol; 2001 May; 19(10):2731-8. PubMed ID: 11352966
[TBL] [Abstract] [Full Text] [Related]
16. breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.
Meijer-van Gelder ME; Look MP; Bolt-de Vries J; Peters HA; Klijn JG; Foekens JA
J Clin Oncol; 1999 May; 17(5):1449-57. PubMed ID: 10334530
[TBL] [Abstract] [Full Text] [Related]
17. [Plasminogen activator inhibitor 1 and prognosis in breast carcinoma].
Mayerhofer K; Stolzlechner J; Yildiz S; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeillinger R; Speiser P
Geburtshilfe Frauenheilkd; 1996 Jan; 56(1):23-7. PubMed ID: 8852782
[TBL] [Abstract] [Full Text] [Related]
